认知顾问在季度损失和减少分析师前景的情况下出售了近70 400个Lyra治疗学股份。 Perceptive Advisors sold nearly 70,400 Lyra Therapeutics shares amid a quarterly loss and reduced analyst outlook.

2025年11月10日,感知顾问有限责任公司出售了18 502股Lyra治疗术(LYRA)股份,将其股份减少了近一半,其中一部分是11月6日到10日出售总额约70 400股的更大销售总额中的一部分。 Perceptive Advisors LLC sold 18,502 shares of Lyra Therapeutics (LYRA) on November 10, 2025, reducing its stake by nearly half, part of a larger sell-off totaling about 70,400 shares from November 6 to 10. 该公司报告,每股每季度损失5.51美元,收入为290 000美元,高于估计数。 The company reported a quarterly loss of $5.51 per share, above estimates, with revenue of $290,000. 使用XTreo技术开发耳鼻喉治疗的Lyra治疗技术,其市场上限为723万美元,并有一个协商一致的“减价”分析师评级,尽管平均价格目标为100.00美元。 Lyra Therapeutics, developing ear, nose, and throat treatments using XTreo technology, has a market cap of $7.23 million and a consensus "Reduce" analyst rating, despite a $100.00 average price target.